Overview

CJC-1295 (Without DAC), also known as Modified GRF (1-29), is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It corresponds to the biologically active 1-29 fragment of GHRH with several amino acid modifications that improve its stability against enzymatic degradation.

The “Without DAC” designation indicates that the peptide lacks the Drug Affinity Complex (DAC) modification, resulting in a shorter biological half-life compared with the DAC-modified version. Because of this, CJC-1295 without DAC has been widely examined in laboratory research investigating growth hormone signaling pathways and pituitary receptor activity.

Due to its structural relationship to GHRH and its interaction with pituitary signaling systems, CJC-1295 without DAC has become a frequently studied compound in research examining growth hormone secretion, insulin-like growth factor pathways, and endocrine regulation. Supplied as a research-grade 10 mg preparation, this peptide is intended solely for laboratory and in-vitro investigation.

Research Background

Scientific investigations have examined CJC-1295 without DAC for its interaction with growth hormone-releasing hormone receptors (GHRH receptors) located on somatotroph cells within the anterior pituitary gland.

The peptide’s amino acid modifications — including substitutions that reduce cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4) — have been studied for their role in improving molecular stability while preserving GHRH receptor binding affinity. This stability allows researchers to examine sustained receptor signaling in experimental models.

Experimental studies have explored how activation of GHRH receptors may stimulate intracellular signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA), pathways associated with the release of growth hormone from pituitary storage vesicles.

In laboratory research models, exposure to CJC-1295 without DAC has been associated with increased circulating growth hormone levels, which may subsequently influence the production of insulin-like growth factor-1 (IGF-1), a protein involved in cellular growth and metabolic regulation.

Because of its GHRH-analog structure and relatively short half-life, CJC-1295 without DAC continues to be studied as a model compound in research examining growth hormone signaling dynamics, pituitary receptor activity, and endocrine pathway regulation.

Common Research Focus Areas

• Growth hormone-releasing hormone (GHRH) receptor signaling studies

• Pituitary somatotroph activation and growth hormone secretion research

• Insulin-like growth factor (IGF-1) pathway investigations

• cAMP-PKA intracellular signaling analysis

• Endocrine regulation and peptide stability research